 AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in four virtual investor conferences in November 2021. 